Please enable Javascript
Oliver Sartor, MD
Oliver Sartor, MD, Mayo Clinic
Articles by Oliver Sartor, MD
PSMAfore: Radioligand Therapy in the Future of Prostate Cancer Treatment
Oliver Sartor, MD
RLT
|
November 21, 2024
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
View More
SPLASH Trial Results Reinforce Benefits of RLT for mCRPC After Progression on ARPI
Oliver Sartor, MD
CRPC
|
October 1, 2024
Dr. Oliver Sartor gives an overview of the SPLASH trial on PSMA-targeted therapies for patients with prostate cancer.
View More
PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC
Oliver Sartor, MD
RLT
|
June 18, 2024
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
View More
PSMAfore: Control Arm and Sequencing Considerations
Oliver Sartor, MD
RLT
|
December 4, 2023
Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.
View More
PSMAfore: Methodology, Nuances, and Implications
Oliver Sartor, MD
RLT
|
December 4, 2023
Dr. Sartor explains in detail the design and methodology, specific findings, nuances, and implications of the PSMAfore trial.
View More